Medical treatment for myasthenia gravis at a Myasthenia Center
https://doi.org/10.14412/2074-2711-2013-2451
Abstract
The paper analyzes the results of treatment in 373 patients included in the Samara Region’s register of myasthenia gravis. The average disease duration was 9.7±7.6 years. Treatment encompassed symptom control with acetylcholinesterase inhibitors and immunosuppressive therapy. To achieve remission and good compensation, most cases needed the combined use of anticholinesterase inhibitors and immunosuppression with glucocorticoids and/or cytostatics. The efficiency of glucocorticoid and cytostatic therapies did not differ essentially. The adverse reactions of the treatment were evaluated. Therapy could achieve stabilization and improvement in 88.2% of cases.
About the Author
Tatyana Valentinovna Romanova
Department of Neurology and Neurosurgery, Samara State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. <div><p>Кузин МИ, Гехт БМ. Миастения. Москва: Медицина; 1996. 224 с. [Kuzin MI, Gekht BM. Miasteniya. Moscow: Meditsina; 1996. 224 p.]</p><p>Лайсек РП, Барчи РЛ. Миастения. Москва: Медицина; 1984. 272 с. [Laysek RP, Barchi RL. Miasteniya. Moscow: Meditsina; 1984. 272 p.]</p><p>Kaminski HJ. Myasthenia gravis and related disorders. Springer Verlag. 2008; 310.</p><p>Санадзе АГ. Миастения и миастенические синдромы. Москва: Литера; 2012. 255 с. [Sanadze AG. Miasteniya i miastenicheskie sindromy. Moscow: Litera; 2012. 255 p.]</p><p>Ишмухаметова АТ, Мусин РГ, Хидиятова ИМ, Магжанов РВ. Эпидемиологическое исследование миастении гравис в Республике Башкортостан. Неврологический журнал. 2006;6:16–21. [Ishmukhametova АТ, Musin RG, Khidiyatova IM, Magzhanov RV. Epidemiological investigation of myasthenia gravis in Bashkortostan Republik. Nevrologicheskiy zhurnal. 2006;6:16–21.]</p><p>Пономарева ЕН. Миастения: клиника, патогенез, дифференциальная диагностика, тактика ведения. Минск: МЕТ; 2002. 175 с. [Ponomareva EN. Miasteniya: кlinika, patogenez, differentsial'naya diagnostika, taktika vedeniya. Moscow: MET; 2002. 175 p.]</p><p>Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. DOI: 10.1186/1471-2377-10-46.</p><p>Matney SE, Huff DR. Diagnosis and treatment of myasthenia gravis. Consult Pharm. 2007;22(3):239–48. DOI: http://dx.doi.org/10.4140/TCP.n.2007.239.</p><p>Kumar V, Kaminski HJ. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep. 2011;11(1):89–96. DOI: 10.1007/s11910-010-0151-1.</p><p>Punga AR, Sawada M, Stalberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve. 2008;37(3):300–7. DOI: http://dx.doi.org/10.1002/mus.20935.</p><p>Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. 2011;16(2):CD006986. DOI: 10.1002/14651858.CD006986.pub2.</p><p>Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43(5–6):428–35. DOI: 10.3109/08916930903518107.</p><p>Diaz-Manera J, Rojas-García R, Illa I. Treatment strategies for myasthenia gravis. Expert Opin Pharmacother. 2009;10(8):1329–42. DOI: 10.1517/14656560902950619.</p><p>Kawaguchi N. Immunosuppressive / immunomodulating therapies in myasthenia gravis-at present and in the near future. Brain Nerve. 2011;63(7):737–43.</p><p>Luther C, Adamopoulou E, Stoeckle C et al. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J Immunol. 2009;183(2):841–8. DOI: 10.4049/jimmunol.0802046. Epub 2009 Jun 19.</p><p>Skeie GO, Apostolski S, Evoli A et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893–902. DOI: http://dx.doi.org/10.1111/j.1468-1331.2010.03019.x.</p><p>Penisson-Besnier I. Treatment of autoimmune myasthenia. Rev Neurol (Paris). 2010;166(4):400–5.</p><p>Hart IK, Sharshar T, Sathasivam S. Immunosuppressant drugs for myasthenia gravis. J Neurol Neurosurg Psychiatry. 2009;80(1):5–6. DOI: 10.1136/jnnp.2008.144980.</p><p>Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;(2):CD002828.</p></div><br />
Review
For citations:
Romanova TV. Medical treatment for myasthenia gravis at a Myasthenia Center. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(4):28-33. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2451
Views: 1272
Email this article 